UCB and Dermira Announce U.S. and EU Regulatory Submissions for CIMZIA® (certolizumab pegol) for the treatment of Moderate-to-Severe Chronic Plaque Psoriasis
UCB’s anti-epileptic drug VIMPAT® (lacosamide) receives EU CHMP positive opinion for both monotherapy and adjunctive therapy in children aged 4 years and older with epilepsy
